Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

XVIVO, Audiocast with teleconference, Q1'24

By Inderes4/24/2024, 12:00 PM
Xvivo Perfusion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Alex Moroianu
00:02 - 17:01

Thank you so much, and welcome to XVIVO's earnings call for the first quarter of 2024. Today, we will start the presentation with the front picture. The slide in front of you right now is a picture of Alex from Australia. She received a heart transplant thanks to XVIVO's heart technology. I think it's an important reminder of why we are actually here, and need to make sure that no one dies waiting for a new organ. And with that, we go to the next slide, which is just today's presenters. And that's me, Christoffer Rosenblad, CEO. Uh, and uh, to the left of me today in the same room for once, I have my CFO, Kristoffer Nordström. Hi, everyone. And with that, we go over to slide three, which is just a quick glance at Q1. And I'm both proud and happy to report the strongest quarter in XVIVO's history. And that Q1 shows improvement in all three business areas. Sales came in at a record of 186 million Swedish kronor. Uh, the gross margins are continuing to show strength. So, also in Q1, I again want to highlight that abdominal gross margin, where we are closing into the 2027 strategic goal of 70% gross margin already. Now this quarter, we show 67% for disposable products, uh, which is a slight improvement from the 2023 full year margin, which was 66%. We plan to improve abdominal gross margin further when we reach economies of scale in production. The adjusted EBITDA shows an improvement to 20%, and I will let Kristoffer Nordström, our CFO, get more into the details on sales, gross margin, and profit later in the presentation. Um, quickly, the growth of thorax is picking up and that mainly comes from higher activity during the quarter. We have historically seen solid growth in Europe with the XPS, but with more feet on the ground. In the US, we see increasing activity there as well. Uh, for example, we have one Active Express customer added during this quarter in the US. The abdominal portfolio continues to grow fast as well. Uh, growth of disposables came in at 46% growth. Uh, we also see higher sales quarter on quarter, which means that we have enabled higher quantities from production this quarter versus the previous quarter. Uh, since the limiting factor for high growth in the abdominal segment is production capacity of disposables. Right now, for the longer term, it's also regulatory approval for liver in the US. Um, as you can see, the production capacity is gradually improving. And we invest to scale up volumes to ten times today's volume for disposables over time. And with that introduction, we go into the highlights, which is slide four. And we go into slide five after that. Um, we of course have to start the highlight section with the report from this year's ISHLT conference in Prague, which was a great success for XVIVO. Uh, the ISHLT Conference is the largest and by far the most important conference for heart and lung transplantation. And we received a warm welcome from all participants. Um, as one example, XVIVO was the most selected exhibitor, and the result from the EU study and NIHP 2019 with XVIVO technology was the most discussed scientific session in the whole program. During the week in Prague. Um, the science from the heart technology shows there is the potential to change the paradigm of heart transplantation, and it's great to show the transplant community how far we actually have come. Uh, ISHLT also held two extremely well attended industry symposia during the conference. Um, the symposia itself and the opportunities for the audience to see what the technology can accomplish in the future was very well appreciated by the transplant community. And many surgeons came up to me afterwards and said that those were the two best parts of the conference because of the good climate for discussion during the industry symposia. And we will talk more about the effect on the next slide, which is slide number six, where we will go into the. More into the heart trial and the results from it. The presentation by Professor Rega attracted by far the most interest, and I do believe that the fantastic top line result was the reason it did. There are three key takeaways. Uh, number one, this is, to our knowledge, the first randomized controlled trial with a superiority design in heart and lung transplantation. And this shows the confidence the clinicians have in XVIVO technology. Uh, number two, the HOPE group. In other words, the one pumped with the technology showed an improvement of 61% for severe PGD versus the control group. This is highly important as an improvement, provided that PGD is the leading cause of early mortality after heart transplantation. And it's accepted that PGD also negatively affects the long-term survival. Um, the third key takeaway from this seminar is that all parts were deemed transplantable after the perfusion. This is important to highlight since cold perfusion offers a safety advantage during especially transportation of an organ. And with that news we go to the next slide, which is slide number seven, which is another groundbreaking result from the heart technology and our heart team. And we did press release this. You heard about it. Um, and it's about the truly groundbreaking transatlantic flight that was published in The Lancet during the quarter. Um, Professor Lebreton has accomplished the first out of seven patients in the PEGASE trial, and that is designed to investigate very long transport times. Um, this case was amazing, not only because it was the first and historic transatlantic flight of a donated heart. Also, the time outside the body of more than 12 hours is truly impressive. Uh, since we have to compare this to the generally accepted time on static storage, which is approximately four hours. Um, given that it was a comparably old donor and a comparatively old recipient, it makes the shipment even more impressive. Um, and it's also important to point out what Professor Lebreton said, that the heart regained normal function directly after transplantation, which is a great achievement and testament that the technology really works. Lastly, I want to mention that the fact that the transport was made on a normal commercial flight is also historic and something we will work more on over time. So all in all, last year the Australian study showed that we can safely increase transport time to 8 to 9 hours and all patients in the study showed zero 30-day mortality. In animal studies, Orebro University recently published that zero heart damage is a good result even up to 24 hours. This should be mentioned in animal studies, but this body of evidence starts to show that safe usage of more hearts at greater distances is possible. This will also open up for more heart transplants and better matching between donor and recipients with good patient outcomes. And as I stated, the commercial air transport is also important because over time it will also open up for cost savings for transplant procedures. If you can use standard modes of transportation, that's normal flights, cars, and trains rather than expensive modes of transportation that we normally see. Heart transplant is needed for our transplant today. And with that news, we will go over to the next slide, which is slide number eight and the recent abdominal milestones. During the last year, we have seen more than 20 publications on liver technology, showing improved patient outcomes on both DBD and DCD grafts after transplantation. But today I want to highlight and speak to another benefit of this technology, and that is the ability to plan transplants to daytime surgery. The background is that no one really wants to work too many nights in a row, but for a transplant team, that is business as usual. After this publication, for liver transplant teams, we believe this could be about to change. The recent Lancet publication from Groningen shows that a liver can safely be perfused up to 20 hours and hence eliminate the need for nighttime liver transplants. By offering a better work-life balance, a transplant team can more easily attract the right competence. So this is not only good for the fact that we can plan transplants in a better way, but it's also very important so we can attract the right type of competence to hospitals that perform transplants. And the last point is, and we said it before, sales for abdominal products right now are mainly limited by supply constraints. The production scale-up of times ten is progressing according to plan. We have invested in machinery and the validation is currently being performed. As also stated earlier, and I can mention again, the kidney transport is growing fast in the two markets we launched it in. The next launch market is the US. And as communicated in the last call in January, the target for full launch in the US is during Q4 2024. If we continue to follow that production scale-up plan as we do now. And with that, we turn our attention to the lung business. And 2024 definitely got off to a great start for lungs. And we see high interest from clinics to start up programs with XPS. In the US, we have a new sales force that is gradually picking up and gearing up. And as one example, we have one more active XPS customer and it was added during the quarter. Then the interest from new customers and the sales pipeline on both sides of the Atlantic is definitely there. So we will keep our sales team busy over the next. Here and further, from that as well. We see a high interest from customers to start even pre-programs. The high interest comes mainly from the ability to safely use more DCD lungs, which is something we are truly grateful for. That's what the XPS and STEEN solution is designed for. This will enable more organs to be used for transplant. And lastly, we will continue to invest to serve our customers in the best possible way. We will invest mainly in clinical expertise and capacity during this year to increase the utilization of EVLP. The next slide will be about the services. And there will be Organ Recovery Services. Christoffer Rosenblad will later in this call give you more details on the service development. I will give you the key highlights here on this slide. All existing contracts are renewed. I truly want to highlight this: Dr. Vincent de Meijer at ISHLT 2024 gave a great speech on the benefits of third-party organ recovery. It was very well received and appreciated by the audience, and I am sure that this will open up business opportunities in the future. We continue to get great feedback from customers regarding the quality of the organ recovery service and the ability that they can grow their programs with great outcomes using our service. So that's something we're very grateful for. I want to state this because it is also important. Every day we continue to improve our service offering and increase capacity to meet the need in the US market. So now we have a great service that we are investing behind. And I'm sure we will see great interest in the future for this service. And with that, we will come to the last part of the highlights and the clinical pipeline. So we go to slide 11, clinical pipeline, and then move on to slide 12 where we will see the regulatory review. Nothing has actually changed. So nothing major has changed since the last time we met. So I will mainly repeat what I said in January. But in the US, the trial is progressing according to plan and our clinical team in the US is working very hard to include all clinics into the trial. At the moment, we have ten clinics out of 20 that are initiated into the trial. And as you can imagine, after I say the interest is extremely high to be part of this US trial in Europe. We have handed in our technical documentation for review and everything is going according to the time plan. We are aiming for a CE mark in Europe in Q4 2024. It's very important to mention that we can't affect the review time to 100%. The good news is that the notified body has been very responsive, even though we know they have a high workload and MDR. Also, the Swedish MPA is responsive and delivers on time. The uncertainty we face still, as reported last time, is how fast the EMA, the European Medicines Agency, can handle their part of the review. Um, but the key is that we have done what we can. We handle the product and clinical files with good quality on time. In Australia and New Zealand, we continue to see high usage of the product. The regulatory approval will be pending the CE-mark in Europe. So from a regulatory view, there is nothing more to add for Australia. But since they use this product regularly, it's the regulatory approval that is not the key here. If we turn our attention to the liver in the US, we have reported earlier that the Liver Assist had been granted Breakthrough Device Designation by the FDA. This means that we get it faster through the FDA PMA process. And it's important to mention, it's also a quality stamp, and that the products are innovative and fulfill a need in the market. We have invested and continue to invest in the organization to run the study and prepare the FDA documentation, and the goal is to submit the IDE application by the end of 2024. And with that, I will hand over to our CFO, Kristoffer Nordström, who will present the financial performance during Q1. And we can go straight to slide 14, which is an.

Unknown
17:01 - 23:50

Overview of the P&L and key group KPIs. So thank you, Christoffer. Uh, yeah. I mean, as Christoffer has emphasized already, we are, of course, very happy with the development in the third quarter. As a recap, sales came in Q1 at 186 million, a new record for us. Um, and more importantly, the organic growth is back, was back on the trajectory and, uh, 32% versus last year. We continue to deliver solid gross margins, 73% versus 75% last year. And I will go in a little bit deeper on each business area, as we go here because the reasons for various gross margins vary depending on product versus service, etc. So, that will come, uh, a bit in. Q1 was 20,000,011 percent. And this was an improvement versus last year with 2% increase in units. EBITDA increased from 25 million to 37 million SEK, which is a record and represented a strong 48% margin for the quarter. So overall, this gave us a promising start to the year and where we continue to improve both top line and profitability. Next slide, please. So, we go into the respective business areas for a while. Starting off, thoracic sales came in at $121 million, a significant increase versus $91 million. Last year, organic growth in disposables was 39%. Here the main driver was EBITDA. And in the United States specifically, global sales grew 65% versus last year. So as I stated earlier, 2024 is off to a great start with good activity at key centers. Um, the strong US sales gave us a 68% share of total global sales, which I also think is a record, and machine perfusion achieved a record of 58% share of total sales. And this impacts the margin a little bit as I will go into. So gross margin in Q1 was 82%, which is lower than last year's 86%. And this was primarily a result of the higher portion of VPI, but also increasing sales. Uh, increasing sales from hot will dilute our margin a bit. Since hot disposables in the US are sold at a reduced price awaiting regulatory approval. And of course, we are still in low scale production with, you know, minimal economies of scale. For now, hot sales in the quarter were 12 million with a 61% gross margin. If we look at the long disposables, though, the margin was 85%. Next slide, please. Before moving on to the abdominal side, we continue to grow steadily quarter by quarter as a result of our solid position in Europe where we have a very strong customer offering in place. Net sales were 44 million SEK, which represents another record quarter for us. Organic growth of disposables in Q1 was 46%. Liver stood for 76% of total sales in the quarter and also for the full year last year. The comparison um, kidney transplant sales were 7 million, a 51% increase versus last year. So here we see a result of our gradual ramp up, uh, and increased production capacity, gross margin level 67%, which is good. As Kristoffer mentioned, uh, 2% units higher than last year. Moving over to services. Final business area. Sales in Q1 were 21 million, which represents a growth of 11%. Um, the customer base from where we ended 2023 remains, and all current contracts have been renewed with increased profitability. And this comes from a new revenue model that we put in place in, uh, in the middle of last year, 2023, where we charge customers per case and not for our provider's dates of availability, which was earlier the case as previously communicated, 2023. That was the year where we put high focus on integration and strengthening our organization and partnerships. As Christoffer mentioned, we continue to strengthen our offering in this quarter, and I really think we can take pride in a high quality service program that has been developed in collaboration with our customers, and that is of utmost importance to mention, actually, um, the gross margin dropped from 65% last year to 36% in this quarter. And this is a result from a mix of, uh, lower recovery case volumes in the quarter, uh, and increased surgeon capacity from additional recruitments in the quarter. That said, we really have an organization in place now that is ready for growth. And with new contracts, also the gross margins will increase. Next slide. Christoffer. Leaving sales a bit to move over to EBITDA and profitability, but I came in at 20% for the quarter isolated. And as you can see here on the slide, also the rolling 12-month trend continues to develop positively. It was a busy quarter for us from an operational standpoint, and we had spending on conferences such as ISHLT market activities. And we also continue to grow our organization with increased profitability. So with that said, we're happy to see that our focus pays off not only in growth of sales, but also contributes to increased profitability. As many times stated before, our ambition is to continue to improve our EBITDA year on year to meet our ambition to achieve 30% in 2027. Final slide for me before I hand over to Christoffer Rosenblad again. Cash flow. Financial position. Q1 was cash positive from operating activities 2,000,006 despite the BSc operations, as I mentioned before, investments amounted to 42 million SEK, primarily spending on US clinical trial and investments into our machine fleet. We ended the quarter with a solid cash position of 511,000,006. So that was all for me, Christoffer.

Alex Moroianu
23:52 - 26:00

Thank you. We're going to go into two pictures of outlook and then into questions, but we can turn first to the long-term outlook, which I believe is slide 21. The long-term outlook is important in order to establish the long-term picture. And that remains the same, that demand for transplant is still ten times the supply. Although against today. According to WHO, the sales value of machine perfusion is also approximately ten times versus static cold perfusion, which is typically a beer cooler or a picnic cooler box with ice and a solution. So we see a great market opportunity in front of us in machine perfusion. Our service models have proven to increase the number of organs to be used for transplantation, especially in the fast-growing DCD organ pool. The main growth drivers are superior clinical results from machine perfusion and the fact that service models reduce complexity and time for the transplant clinic. Hence, machine perfusion service models for normal and extended criteria or DCD grafts will drive growth in the near future. Lastly, to grow all the way to ten times in number of transplants the company believes is possible with the current human donor pool. However, over time, new innovative sources of organs will probably be used, for example, xenografts or printed grafts, etc., for both machine perfusion and new sources of organs. Ex vivo has a proven product line. This puts us in a unique position on the market today. And with that, we zoom in a little bit more near term to 2024 and our outlook. One, it's important to mention, again, we keep a razor-sharp focus on our key priorities.

Unknown
26:02 - 26:03

Two.

Alex Moroianu
26:03 - 27:22

After this city, we realized and we will increase the focus and resources on both the US Heart trial and the EU Heart launch and in parallel. For lungs, there is a great interest from customers to start an ex vivo program. And we will invest to capture that interest. An increase utilization of our even on the express with the solution. Number four, we will increase production capacity by at least ten times to meet the increased demand we see for abdominal products. And lastly, support our growing clinical program with service models to reduce the complexity in the transplant process. And during the year, we will also develop a successful product service revenue model to meet the Transplant Clinic's logistical needs, which we know are there and we don't have a good enough offering today. So that will be developed throughout the year. So with that, that was the outlook for the long term and the year. And with our vision in mind that nobody should die waiting for a new organ. We open up for questions. Thank you so much.

Unknown
27:25 - 27:46

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Simon Larsen from Danske Bank. Please go ahead.

Unknown
27:49 - 28:15

Yes. Good afternoon, gentlemen. Two questions from my end, please. Uh, first one, I mean, a very impressive performance from the lung franchise this quarter. Uh, if I'm not mistaken, you know, machine perfusion as part of the consumables grew some 70% year over year. So were there any one-offs in the quarter? I mean, thinking orders pushed from Q4 into Q1, something else, or just very good underlying demand. So any more flavor here would be helpful.

Alex Moroianu
28:16 - 28:53

Thank you, Sir Simon. Yeah. To give some flavor, we had a comparably weak Q4 last year, so we cannot, uh, as you say, take away the fact that probably some orders ended up on this side of the quarter or some orders in this quarter rather than the last one. But we do see high interest, and, uh, we do see an increased activity in LP during this quarter that we certainly hope will continue. But that is nothing we know for sure, but we will at least do our best with our sales force to meet that interest.

Unknown
28:54 - 29:04

Yeah. So you think, is this like a plausible level of sales that we should expect going forward, or should we expect this to come down a bit here sequentially and further into the year?

Alex Moroianu
29:05 - 29:39

I think that's a great question. I think what we should remember is also that compared between Q1 and Q2 for last year, were comparably slower quarters to Q2 and Q3 comparables. I think that is also important to keep in mind. Um, it's always hard. This is one quarter. I think we need to see at least 3 or 4 quarters of continued growth before we should adjust too much in our model, so to say.

Unknown
29:41 - 29:45

Yeah, yeah. Makes sense. And the final one from my end, you mentioned one.

Unknown
29:45 - 29:59

New customer that went live with the XPS Technology in the US during the quarter. I mean, it would be extremely helpful if you could provide us with some estimate of what a customer like that could actually bring in per year, once up and running with the experts fully in terms of sales for you.

Alex Moroianu
30:00 - 30:17

I mean, a very good, let's say, larger program. We could easily do 50 to 60 operations on the XPS per year when they're fully up and running.

Unknown
30:19 - 30:20

Yeah. Okay, cool.

Unknown
30:21 - 30:22

Uh, thanks.

Unknown
30:22 - 30:23

That's all from us.

Unknown
30:23 - 30:24

From my end, thanks so much.

Unknown
30:25 - 30:25

Thank you.

Unknown
30:29 - 30:35

The next question comes from Jacob Lemke from CB. Please go ahead.

Unknown
30:37 - 31:02

Hi and good afternoon. I have a few questions. I'll take them one by one. Starting on EVLP. I mean, you sound a bit more positive on the sort of customer demand or customer interest here than recently. Would you say that you're seeing some sort of tipping point where you're moving towards more inbound interest rather than outbound? You're pushing this.

Alex Moroianu
31:05 - 31:39

That's a great question. Again, I have to say this is something we need a couple of quarters to answer with full confidence. We do see the interest there, and we see that our sales force is gearing up. We are getting better at meeting that interest every day. I would say it's still early days. And I would definitely wait a couple of quarters before I say something with 100% confidence. But in terms of interest, I can confirm that it's there.

Unknown
31:43 - 32:04

Okay. Uh, and then on the kidney, I mean, it seems like the production movement and improvements are moving according to plan. I think it would be interesting to hear you talk a bit more about the demand situation. Such as if there's already firm orders in place that you can start to deliver on once production improves.

Unknown
32:06 - 32:06

Um.

Alex Moroianu
32:07 - 32:10

Right now we have.

Unknown
32:10 - 32:10

Had.

Alex Moroianu
32:11 - 33:03

Two successful launches but very limited, one in the Netherlands and one in Italy. And there we see that use is picking up and that is great when now we turn our focus to the US and we have done a pre-launch activity where we do see that they are using the kidney transplant. So we but we don't dare to, let's say, fully launch until we know we have enough products on the shelf. Uh, but I believe that. So we don't have any confirmed orders yet, but we have a very high interest for the product, and it meets the need that is there not only in the US market but on the global market, that there is a high need for a better kidney product that can take care of all DCD grafts. So transplantation with good patient outcomes. So we are confident that there will be.

Unknown
33:03 - 33:10

A good launch in the US on board. I mean they don't want okay.

Unknown
33:11 - 33:29

Uh and then um it's done. Uh services you mentioned that all customers are on a new contract model here. And I noticed the price was a bit or average revenue per case was a bit higher here in Q1. Is this the level we should expect going forward?

Unknown
33:31 - 33:34

And. Yes.

Unknown
33:34 - 33:59

The, uh. This is definitely a model where we make more money per contract because we were taking on a lot of risk with the older models. So I think the numbers you will see from now on, in relation to the cases should have, will reflect the correct ASP and that could be used as a guidance.

Unknown
34:03 - 34:22

Okay, great. And then this finally would be interesting to hear. You know, we'll talk a bit more on the heart product. Maybe you know, how the customer reception has been following the very strong results here. And now that, uh, you are only a few quarters away from launching this in Europe?

Alex Moroianu
34:23 - 35:21

No, I can do that. I mean, it was overwhelming, the reception we got at this city where all the world's opinion leaders and transplant surgeons were present, but probably some were at home doing transplants as well. But, I mean, the reception was just fantastic. And the interest is through the roof. Uh, I think everybody starts to realize now what this technology can accomplish, not only in terms of better donor matching, longer distances, we can take care of organs that we could not do. We can do cases we just couldn't do before. And, and uh, so that's something we definitely will invest more into and have a higher focus on going forward because, uh, I believe we see it as a technology that's going to just change how transplants are made in terms of hearts.

Unknown
35:26 - 35:26

Okay.

Unknown
35:26 - 35:28

Thank you very much. That's all from me.

Unknown
35:28 - 35:29

Thank you so much.

Unknown
35:35 - 35:40

The next question comes from Ulrich Ratner from Carnegie. Please go ahead.

Unknown
35:42 - 35:42

Thank you very much.

Unknown
35:42 - 35:44

Much appreciated. And I'm optimistic.

Unknown
35:44 - 36:17

Going back to a few questions already asked. Uh, but exceptionally strong EVLP growth here in the US. And I know you were a bit muted at the Q4 call, and you were talking about how it takes time to train your expanded sales force. Should we see this as a sign of the process being ahead of your expectation, or is this purely due to superior underlying demand in the market?

Unknown
36:19 - 36:19

Uh, I.

Alex Moroianu
36:19 - 37:02

I think the main reason is definitely that the underlying demand is higher than we anticipated. Uh, that's the main reason. But that said, I also must say that I'm proud of the salesforce that is very new. What they have accomplished in the short time and the steep learning curve they have, to add an active customer that quickly is a true accomplishment that I'm truly proud of. So, it's both, but yes, the main reason is definitely the high interest and the high underlying growth from existing customers. Driving growth right now, it's not so much new customers.

Unknown
37:03 - 37:04

Okay. Great.

Unknown
37:04 - 37:49

And you also talked about expanding your service offerings in the US. And I'm guessing what you're trying here is to replicate more of that of TransMedics. Given your product portfolio and their societal service offering would be a good match. And also note that one of your head of marketing in the US, Kelly, was previously part of trans. So, what does that bring to the table? What should be expected from service offerings in the US in the coming quarters? Start heading up towards full-scale kidney tests. Um, launch in the US as well as building up to heart and liver perfusion. Approval in the market here in a few years.

Alex Moroianu
37:49 - 39:57

That's a great question. I will let Christoffer Rosenblad answer your question more in depth, but before that, I want to mention that we do see and have seen for a long time the need for. For a good service product offering, the reason is that the transplant process takes longer, and the heart, on average, takes 29 hours. And if we're going to do ten times more transplants in the near future, the transplant teams won't grow tenfold in terms of resources. So we need to support them within the first 24 hours, and provide better technology in order for them to do ten times more transplants in the US market. So, that is the reason behind why we believe so much in this strategy and that we believe that it will be a winner over time. And that's why we work so hard on improving quality, improving communication, improving the customer offering, etc., because we want to nail it when we go large scale. Last thing I want to mention is that I definitely think when we come to transportable devices, our product service offering will fit better. So if we think about kidneys and hearts, that's a plug-and-play model, which is easier. But we believe already with the XPS and later with the liver, which is more back-to-base type of machines, that a service model will be advantageous and drive a lot of growth for us. For example, liver perfusion in Italy is five times higher than in a comparable country in Europe, very much due to our service offering model on the perfusion side of the liver device. So we have seen it works. We believe it will work in the future and actually believe it will be a must for the future. But to address the expectations for next quarter, I will let Alex Moroianu answer that question.

Unknown
39:58 - 39:58

Yeah.

Unknown
39:58 - 41:04

No, I think, you know, we see this as two phases where we are now in an interim phase of where we are strengthening and developing our currently recovering business in the US. The end stage is, of course, when we have both our transportable products, kidney and heart, on the market. And we can really see synergies from integrating service into our product offering. But up until then, you know, we have a platform for growth now. We have continuously improved. And we will, I think our aim is to ensure that we learn more and more about the customers' needs, add more customers. So we have a robust position and organization when we finally have our regulatory approvals in place, and I think we can expect gradual growth from where we are today. Um, and we will try to do our best to also have, you know, continuous surgical capacity in place. So that always goes hand in hand.

Unknown
41:07 - 41:23

Okay, great. And just to follow up on that, as you have recruited Kelly recently, who has been part of TransMedics. Uh, can she bring some additional clarity on how you should. I perform this.

Unknown
41:24 - 41:43

Absolutely. She is on board now. Great ideas and a very valuable addition not only to the US team but also to the global team. So she's still one of them who has not been here that long. But I think we can already see that she brings a lot to the table, especially on the service side, of course.

Unknown
41:44 - 42:13

A great addition. And if I were to move to abdominal and exceptional growth again, especially for liver in Europe. But out of curiosity, which markets are growing? I'm guessing Italy and the Netherlands are fairly well-penetrated markets. So this must mean that you're experiencing quite strong growth outside of these two key markets.

Unknown
42:14 - 42:14

Yes.

Alex Moroianu
42:14 - 43:08

Is that question being mentioned that there is a lot of penetration and growth still to be done in both the Netherlands and Italy, but definitely, we see more of a wider growth everywhere in Europe right now. We had a couple of success stories a year ago with reimbursement in France, for example, for liver, which really helped growth there. As I mentioned earlier, we have had 20 really good publications on liver just in the last 12 months, showing superior outcomes, both on DBD, on extended criteria grafts, on DCD grafts. So we see that that has spurred a lot of interest together with better reimbursement. We see widespread growth all over Europe right now.

Unknown
43:11 - 43:46

Great. Thank you. And the last question on my end. So obviously XVIVO Perfusion is a great product. It has significant clinical support. It could also be fairly easy to implement. But given the sort of commercial success of delivery in Europe, I believe it would be of high importance for you to get the liver device on the US market. And you touched upon IDE for liver. Uh, but can you just give us some clarification on what's left if you start up the liver study?

Unknown
43:48 - 43:49

Uh, I mean, to start.

Alex Moroianu
43:49 - 44:03

To deliver the study, you need to agree on the FDA, on an IDE, and we are currently designing the study and will meet quite shortly.

Unknown
44:03 - 44:04

With the FDA.

Alex Moroianu
44:04 - 44:58

Proposed study design. That will be a negotiation. Of course. Uh, there is also product documentation that needs to be approved, uh, where even though it's a commercial product in Europe, there could be product gaps between our CEO Mark, and what the FDA would like. So that's also a discussion to be had with the FDA. Regarding if there are any gaps in terms of animal testing or other product-related issues. Um, then out of experience, I know that the FDA always wants to have a usability test done in the U.S. Solid with us users as a quality measure from the FDA side. So there are a few steps still to be taken on the liver side before we can get an IDE.

Unknown
45:00 - 45:22

Okay, great. And last question on my end. Um, it's heart sales in the quarter. How much of the reported part sale is related to Australia and New Zealand? Compassionate use and how much is related to reimbursed sales? Sort of. Led the US clinical study.

Unknown
45:24 - 45:27

I think I would need to come back to you on that one. Um, Ulrich.

Unknown
45:29 - 45:30

Fair enough.

Unknown
45:30 - 45:30

Enough.

Unknown
45:31 - 45:37

Thank you. Well, congratulations again on a stellar quarter. And, uh, as for answering my questions.

Unknown
45:38 - 45:39

Thanks. Thank you.

Unknown
45:41 - 45:48

The next question comes from Jonathan Andersen from DNB Markets. Please go ahead.

Unknown
45:52 - 45:53

Hey guys.

Unknown
45:53 - 45:56

And congratulations on a great quarter. Um.

Unknown
45:57 - 46:00

I have a couple of questions. I think that I will.

Unknown
46:00 - 46:00

Begin.

Unknown
46:00 - 46:01

With abdominals.

Unknown
46:01 - 46:03

So when.

Unknown
46:04 - 46:07

Answering and ramping up kidney.

Unknown
46:07 - 46:08

Transport.

Unknown
46:08 - 46:09

In the US.

Unknown
46:09 - 46:14

How will the commercial setup look, uh, during.

Unknown
46:14 - 46:16

Late Q2 and going.

Unknown
46:16 - 46:17

Forward.

Unknown
46:17 - 46:18

And saying anything on.

Unknown
46:18 - 46:19

That would be.

Unknown
46:19 - 46:19

Helpful?

Alex Moroianu
46:21 - 46:27

With commercial setup. Do you mean, um, our field force for launch?

Unknown
46:27 - 46:28

Exactly. Yes.

Alex Moroianu
46:28 - 46:33

Okay, great. Great. Uh, we have, uh, uh, if you call it.

Unknown
46:33 - 46:33

Field.

Alex Moroianu
46:34 - 47:50

Focus within mainly three competencies. One is, of course, sales, where we have three persons to start with, one for the West and one for the East. And then we have a clinical force that we will gradually need to grow the more customers we include in the launch, that will make sure they use the product. Right, and be there for the customers. And then we will have a technical service department that we will also gradually grow with the number of machines we have on the market, the more technical issues you will have and the more you have to do service on them. Uh, so that's pretty much what the team will look like right now. Then we will receive support from both the US marketing team and here at headquarters with support for the clinical trials. If there are any investigator-driven clinical trials that they want to be done, we support with the health economic studies and reimbursement support going forward. So that's how the organization for the launch looks right now.

Unknown
47:52 - 47:53

Clear.

Unknown
47:53 - 47:54

Um.

Unknown
47:54 - 47:55

And just looking at the.

Alex Moroianu
47:55 - 47:56

The.

Unknown
47:56 - 47:59

Potential launch here in Q4.

Unknown
47:59 - 48:00

The heart disease.

Unknown
48:00 - 48:05

Transport in Europe on the back of the supply issues.

Unknown
48:05 - 48:06

With, with.

Unknown
48:06 - 48:16

The kidney, what lessons have you learned and are you confident in not reaching that to some extent.

Unknown
48:16 - 48:17

Supply.

Unknown
48:17 - 48:21

Issues when launching this product.

Unknown
48:22 - 48:22

Oh, that's.

Alex Moroianu
48:22 - 49:01

Ah, that's a great question. Uh, we have learned a lot. And we have been able to scale the production of hearts, actually faster than kidneys, already. And given the interest we've received, we have included the heart products into the production scale-up project. Um, and two, we are running a program to increase production, uh, with the current production setup, uh, which fortunately, is more scalable than the production setup we saw before.

Unknown
49:02 - 49:02

For kidney.

Alex Moroianu
49:03 - 49:16

Transplant. So, we learned a lot from that experience. And we are taking early actions, and we're taking more decisive actions on the heart already now.

Unknown
49:19 - 49:19

Great.

Unknown
49:20 - 49:21

Lastly.

Unknown
49:21 - 49:44

This might be a bigger picture and long-term, but given your clinical data and market position and the underlying market demand, do you feel hampered about your profitability target since you do not have any sales?

Unknown
49:44 - 49:45

Growth, financial.

Unknown
49:45 - 49:52

As of today, would it make sense to switch? Towards more growth.

Unknown
49:52 - 49:53

Focused.

Unknown
49:53 - 49:54

An oriented.

Unknown
49:54 - 49:56

Target going forward.

Alex Moroianu
49:57 - 50:23

That is a great question. And to give you a straight answer, no, we don't feel hampered. It's more of a guidance that we should follow. If we do something, we should do it with efficiency. And, we should do it to ensure long-term profitability and make sure we don't take any, let's say, crazy bets in the market. So it's more of a guiding target. We have to make sure that.

Unknown
50:23 - 50:24

We.

Alex Moroianu
50:24 - 50:35

If we do something, we do it with respect to the shareholders' money that you guys have entrusted to us.

Unknown
50:35 - 50:38

So we don't feel.

Alex Moroianu
50:38 - 50:45

Feel no constraints in that way. But that being said, we might come to a launch where we feel we need.

Unknown
50:45 - 50:45

To.

Alex Moroianu
50:45 - 51:15

To over-invest for a quarter or two, and the nice straight line from here to 30% might get a bump up or down from time to time. And we do feel that that would be communicated early enough if we see that need, so everybody would be aware of it. But no, we don't feel hampered in any way. We invest at a healthy level.

Unknown
51:18 - 51:41

Makes sense. And then maybe just one more question. You have done some really rational M&A activities for the last years. Do you see any M&A opportunities down the road, maybe in the service business area or in marketing, and what's your view on that?

Unknown
51:42 - 51:44

At.

Alex Moroianu
51:44 - 52:38

We are always open to M&A. If it adds value for the company and is strategically the right move, we constantly look for M&A opportunities. Uh, it defeats our purpose. Uh, especially if we take, let's say, a strategic step where we believe it's much more efficient to buy a company rather than develop that competence or market position or what we want to achieve. So to say, if it's quicker to buy or better to buy and it makes economic sense, then we would buy it rather than do it ourselves. So it's always a choice to do it ourselves. We could always partner with someone, we could always license, or we could always acquire something. So we always ask ourselves those questions. What does make more sense for this purpose? For what we want to achieve?

Unknown
52:41 - 52:41

Cool. Great.

Unknown
52:41 - 52:44

And once again, congratulations on a great quarter.

Unknown
52:45 - 52:46

Thank you.

Unknown
52:51 - 52:56

The next question comes from Johan Aeneas from Red Eye. Please go ahead.

Unknown
53:00 - 53:00

Great.

Unknown
53:00 - 53:46

Thanks for taking our questions. And yet again, congratulations on a good quarter. A very good quarter. Um, some nitty-gritty questions you alluded to. If you are to invest more intensively than you are currently investing in capacity and commercially, uh, Q1 opex wise came in, at least in our view, a bit on the low side. What to expect. There you are. Um, you are targeting the US market, increasing the commercial activity capacity. That might not always end up in opex, but you're doing several things.

Unknown
53:48 - 54:57

Yeah. Thank you, everyone. Um, I think, you know, overall it's a bit of guidance here. Um, where if you look at our opex, where we will grow, um, as we go is primarily on the marketing and sales side. That is where we have the quickest return on investment. Um, and I also think by saying that, expanding our opex on commercial will also be followed by a quick growth as well. So I do not foresee that that would dilute our margins. With the caveat that Christoffer said that it could be 1 or 2 quarters where we take a deliberate decision to do extended investments. Um, but that's where we will invest, uh, gradually, um, as we grow, uh, admin and research will be, I think, the levels we saw in this quarter are probably, you know, representative, um, for the next quarters or so as well.

Unknown
54:59 - 55:26

Great. Thank you. Also, a small part, but critically important, as you explained earlier on the services side, it's obviously important to secure additional contracts. Anything more on the contract pipeline, and perhaps you can do more to conclude this pipeline and the commercial sales process.

Unknown
55:27 - 55:28

Yep.

Unknown
55:28 - 55:59

No, I mean, with our strong offering that we have developed, we're optimistic. Um, we also got the chance to truly engage in an international setting, with high attendance from US stakeholders, we were able to present this as well as I felt. So I think we have a good momentum now. We have learned, I mean, there are cycles of selling in a contract. It takes a few months. But there is a pipeline of interesting customers at the moment. Absolutely.

Unknown
56:02 - 56:02

Yeah.

Unknown
56:03 - 56:27

And on the heart solution, we have published a great deal of achievements, and we're looking forward to the US study. Anything to be said about the initial centers? You ten are active and the prospects of any of them sort of concluding their part, uh, in the second half of the year.

Unknown
56:29 - 56:31

Um, I mean, what.

Alex Moroianu
56:31 - 57:22

To be said on the US trial? Um, it's mainly that I mean, we've got the best of the best centers right now, um, because we are in the comfortable situation of almost being able to choose, um, which doesn't happen that often. There is a huge interest, both from those who are in the trial and from others. The scientists who want to get into the trial. Then it's always when you run a clinical trial, you run it at the highest pace you can, but you also want to make sure that you keep your inclusion, exclusion criteria, etc. But we have a very high pace and we are running according to plan. So we will definitely and most probably see a couple of the bigger ones concluding their portion. During this year.

Unknown
57:22 - 57:23

Yeah.

Unknown
57:25 - 57:42

Okay, great. And yeah, it's obviously important to get traction from the centers. And also, you mentioned that interest from centers not actively participating. Is there any way to activate these centers ahead of the approval?

Alex Moroianu
57:43 - 57:49

The straight answer to that is yes. Right now, I've ordered the teams to have 100% focus.

Unknown
57:49 - 57:50

On

Alex Moroianu
57:50 - 58:16

The current trial, because that is needed to not drop the ball on the trial. But the answer is yes. And we are in the planning phase to see what other trials we can do on U.S. soil. That would increase the confidence, both from a regulatory approval viewpoint from the FDA, and they would be interested in, also to build knowledge on U.S. soil around the technology. I think the

Unknown
58:17 - 58:18

The key

Alex Moroianu
58:18 - 58:50

Takeaway also from my assessment was how the U.S. condition was quite impressed with the confidence that the European nations had around the technology. But there is a difference. I mean, most U.S clinics use the technology for four months versus four years in Europe. So, of course, that gives a greater confidence to use the technology for a longer time. But I think that definitely inspired interest to take the technology to the next level also in the US. So, we are planning for that.

Unknown
58:51 - 58:53

Great. Thanks for answering the questions.

Unknown
58:54 - 58:54

Thank you.

Alex Moroianu
58:54 - 58:56

So much.

Unknown
58:59 - 59:06

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad.

Alex Moroianu
59:08 - 59:14

And with that, I want to say that we can take one more question, but then unfortunately, we need to go into the next meeting.

Unknown
59:16 - 59:24

There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Alex Moroianu
59:30 - 59:49

Thank you so much. There are no written questions. Great, great questions today, I appreciate them. And with that, we conclude this Q1 report call. And we're looking forward to meeting you in July for the Q2 call. Thank you so much.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…